GEHC demonstrates stronger value characteristics with a Zacks Rank #2 (Buy), improving earnings outlook, lower forward P/E ratio (12.98), superior Value grade (A), lower PEG ratio (1.69), and lower P/B ratio (2.63), making it the preferred choice for value investors.
GEHC has a superior Zacks Rank #2 (Buy) indicating improving earnings estimate revisions, a better Value grade of B, lower forward P/E ratio (14.54 vs 19.67), and lower P/B ratio (2.95 vs 5.64), making it more attractive for value investors.
Company missed Q1 earnings estimates ($0.99 vs $1.05 consensus), cut full-year EPS guidance, experienced a 13% stock price decline, and is subject to a securities law investigation by a major plaintiffs' law firm.
Company missed Q1 2026 earnings consensus estimates, reduced full-year guidance, experienced a significant 13% stock price decline, and is now subject to a securities investigation by a major law firm for potential violations of federal securities laws.
Company missed Q1 earnings consensus estimates, reduced full-year EPS guidance, experienced a significant 13% stock price decline, and is now subject to a securities investigation by a law firm on behalf of shareholders, indicating potential regulatory and legal risks.
Stock declined 11.3% following Q1 2026 earnings announcement. The company faces significant cost pressures ($250 million in increased costs) that will reduce EPS by $0.15 in 2026 despite mitigation efforts. Long sales cycles delay the ability to pass costs to customers through price increases, creating near-term margin compression.
Articles that tag GEHC but are mainly about other companies.
Listed among leading SaMD companies with strong portfolio in medical imaging and diagnostic software, positioned to benefit from market expansion and AI integration trends.
Listed as a major key player in the rapidly growing ultrasound AI market with strong projected growth of 26.62% CAGR through 2035
Actively expanding market presence through strategic acquisitions (Intelerad Medical Systems, Ambra Health) in the high-growth enterprise imaging sector.
Company achieved significant regulatory milestone with FDA 510(k) submission and CE Mark approval for advanced molecular imaging technology. The StarGuide GX system positions GEHC well in the growing theranostics market, which is projected to grow at 4.6% CAGR through 2030. The technology addresses emerging clinical needs and supports next-generation radioligand therapies.
Mentioned only as a peer comparison for valuation multiples in the medical device sector. No specific sentiment is implied about the company itself.
While VASO's strong performance is partially driven by its exclusive representation agreement with GE HealthCare, the relationship also represents a concentration risk. GE HealthCare is mentioned as a dependency factor that could limit VASO's operating consistency if product availability or delivery timing issues arise.
Listed as a featured company in smart hospital solutions and digital health initiatives
Listed as a key market player in the growing infant heart monitor market with strong market presence and expected to benefit from the 10.85% CAGR growth through 2035.
GE Healthcare unveiled a new high-tech NICU monitoring system in March 2024 designed to enhance real-time patient monitoring and early diagnosis of neonatal issues, demonstrating active innovation and market participation in the growing neonatal care sector.
Listed as a key player in the growing healthcare command centers market, positioned to benefit from the projected 10.8% CAGR growth through 2034.
Mentioned as a major incumbent investing aggressively in AI-augmented cardiac imaging with advanced reconstruction technologies, but no specific recent developments or performance metrics provided in the article.
Leading healthcare technology provider in the computer vision market, well-positioned to capitalize on growth in medical imaging diagnostics and surgical assistance applications.
Key player in healthcare analytics market benefiting from digital health transformation and AI adoption
Company reported declining earnings per share, reduced full-year guidance, and disclosed unexpected $250 million in additional input costs due to inflation, resulting in sharp stock price decline and triggering securities investigation.
Dropped 13% on margin pressure from tariffs
Listed as a key market player in the growing cell culture media bags market, positioned to benefit from the 5.8% CAGR expansion through 2035.
Key company in the respiratory care devices market experiencing substantial growth driven by technological advancements and increasing global healthcare infrastructure investment.
Announced commercial availability of integrated surgical visualization system with Medtronic, expanding product capabilities and market reach in neurosurgery applications.
Listed as a major company in the ambulatory surgical equipment market, which is experiencing strong growth at 7.85% CAGR with expanding demand across regions and equipment types.
Identified as a key competitor in the expanding IoT healthcare market, well-positioned to capitalize on digital transformation and connected health infrastructure investments.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
